<DOC>
	<DOC>NCT00989196</DOC>
	<brief_summary>This is a clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII, a newly developed human cell-line derived recombinant FVIII concentrate in previously treated patients with severe Hemophilia A.</brief_summary>
	<brief_title>Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A (FVIII:C &lt;= 1%) Male subjects between 12 and 65 years of age Body weight 25 kg to 110 kg Previously treated with FVIII concentrate for at least 150 EDs Other coagulation disorder than hemophilia A Present or past FVIII inhibitor activity</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>